Protein losing enteropathy: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 7: Line 7:
==Overview==  
==Overview==  


'''Protein losing enteropathy''' is the loss of plasma proteins from the gastrointestinal tract caused by an array of abnormalities
Protein losing enteropathy is the loss of plasma proteins from the gastrointestinal tract caused by an array of abnormalities


==Common Causes==
==Common Causes==
Line 15: Line 15:
#[[Lymphatic obstruction]]
#[[Lymphatic obstruction]]


===Primary Gastrointestinal Diseases ===
===Primary Gastrointestinal Diseases===


=====Mucosal Erosions/Ulcerations=====
=====Mucosal Erosions/Ulcerations=====
Primary gastrointestinal diseases causing erosion or [[ulceration]] of the [[mucosa]] of the [[gut]] leading to fecal loss of proteins such as:
Primary [[gastrointestinal]] diseases causing erosion or [[ulceration]] of the [[mucosa]] of the [[gut]] leading to fecal loss of proteins such as:


*[[Inflammatory bowel diseases]] (Crohn disease, Ulcerative colitis)
*[[Inflammatory bowel diseases]] ([[Crohn disease]], [[Ulcerative colitis]])
*[[Malignancies]] involving the gut mucosa
*[[Malignancies]] involving the gut [[mucosa]]
*Graft vs. host disease
*Graft vs. host disease
*Esophageal and gastric erosions or ulcerations
*[[Esophageal]] and [[gastric]] erosions or [[Ulceration|ulcerations]]
*[[Carcinoid syndrome]]
*[[Carcinoid syndrome]]
*Bacterial infection with [[Clostridium difficile]] causing [[pseudomembranous colitis]]
*Bacterial infection with [[Clostridium difficile]] causing [[pseudomembranous colitis]]
*Parasitic infection with [[Giardia]]
*[[Parasitic]] infection with [[Giardia]]


=====Non-Erosive/Ulcerative Mucosal involvement=====
=====Non-Erosive/Ulcerative Mucosal involvement=====
Line 34: Line 34:
*[[Hypertrophic gastritis]]
*[[Hypertrophic gastritis]]
*[[Connective tissue disorders]]: [[Systemic lupus erythematosus]]
*[[Connective tissue disorders]]: [[Systemic lupus erythematosus]]
*Cutaneous [[burns]]  
*[[Cutaneous]] [[burns]]


===Lymphatic Obstruction===
===Lymphatic Obstruction===
Conditions responsible for causing lymphatic obstruction leading to the leakage of lymph into the lumen of gut such as:
Conditions responsible for causing [[lymphatic]] obstruction leading to the leakage of [[lymph]] into the lumen of gut such as:


*[[Lymphoma]]
*[[Lymphoma]]
*Congenital or acquired lymphatic diseases
*[[Congenital]] or acquired lymphatic diseases
*Lymphatic [[filariasis]]
*Lymphatic [[filariasis]]
*[[Sarcoidosis]]
*[[Sarcoidosis]]
Line 47: Line 47:
*[[Fortan surgical procedure]]
*[[Fortan surgical procedure]]
*[[Cirrhosis]] with [[portal hypertension]]
*[[Cirrhosis]] with [[portal hypertension]]
*[[Retroperitoneal fibrosis]] <ref name="pmid26446687">{{cite journal| author=Furfaro F, Bezzio C, Maconi G| title=Protein-losing enteropathy in inflammatory bowel diseases. | journal=Minerva Gastroenterol Dietol | year= 2015 | volume= 61 | issue= 4 | pages= 261-5 | pmid=26446687 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26446687  }}</ref> <ref name="pmid25618488">{{cite journal| author=Amiot A| title=[Protein-losing enteropathy]. | journal=Rev Med Interne | year= 2015 | volume= 36 | issue= 7 | pages= 467-73 | pmid=25618488 | doi=10.1016/j.revmed.2014.12.001 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25618488  }}</ref> <ref name="pmid31194423">{{cite journal| author=| title=StatPearls | journal= | year= 2020 | volume=  | issue=  | pages=  | pmid=31194423 | doi= | pmc= | url= }}</ref>
*[[Retroperitoneal fibrosis]]  


==Complete Differential Diagnosis Of Underlying Causes==  
==Complete Differential Diagnosis Of Underlying Causes==  
Line 89: Line 89:


==Diagnosis==
==Diagnosis==
As [[hypoproteinemia]] is the key factor in evaluating a patient for protein losing [[enteropathy]], other common causes of hypoproteinemia such as [[nephrotic syndrome]], impaired protein synthesis due to [[chronic liver disease]] and [[malnutrition]] must be excluded first.<ref name="UmarDiBaise2010">{{cite journal|last1=Umar|first1=Sarah B|last2=DiBaise|first2=John K|title=Protein-Losing Enteropathy: Case Illustrations and Clinical Review|journal=American Journal of Gastroenterology|volume=105|issue=1|year=2010|pages=43–49|issn=0002-9270|doi=10.1038/ajg.2009.561}}</ref>
As [[hypoproteinemia]] is the key factor in evaluating a patient for protein losing [[enteropathy]], other common causes of hypoproteinemia such as [[nephrotic syndrome]], impaired protein synthesis due to [[chronic liver disease]] and [[malnutrition]] must be excluded first.


==='''Laboratory Studies'''===
==='''Laboratory Studies'''===
As the most prominent laboratory finding is a decrease in serum concentration of [[albumin]] and [[globulin]], the diagnostic work up protein losing enteropathy consist of quantitative measurements of [[Alpha-1 antitrypsin]] or <sup>51</sup>Cr-albumin.<ref name="LevittLevitt2017">{{cite journal|last1=Levitt|first1=David|last2=Levitt|first2=Michael|title=Protein losing enteropathy: comprehensive review of the mechanistic association with clinical and subclinical disease states|journal=Clinical and Experimental Gastroenterology|volume=Volume 10|year=2017|pages=147–168|issn=1178-7023|doi=10.2147/CEG.S136803}}</ref>
As the most prominent laboratory finding is a decrease in serum concentration of [[albumin]] and [[globulin]], the diagnostic work up protein losing enteropathy consist of quantitative measurements of [[Alpha-1 antitrypsin]] or <sup>51</sup>Cr-albumin.


*[[Alpha-1 antitrypsin]] (A1AT) used as an endogenous marker is a sensitive and inexpensive laboratory test performed to diagnose protein losing enteropathy and has become the current standard for quantitating protein losing enteropathy.<ref name="pmid2475983">{{cite journal| author=Karbach U, Ewe K| title=Enteric protein loss in various gastrointestinal diseases determined by intestinal alpha 1-antitrypsin clearance. | journal=Z Gastroenterol | year= 1989 | volume= 27 | issue= 7 | pages= 362-5 | pmid=2475983 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2475983  }}</ref> Measurement of fecal volume and fecal loss of alpha-1 antitrypsin depicts the plasma concentration of alpha-1 antitrypsin as;
*[[Alpha-1 antitrypsin]] (A1AT) used as an endogenous marker is a sensitive and inexpensive laboratory test performed to diagnose protein losing enteropathy and has become the current standard for quantitating protein losing enteropathy. Measurement of fecal volume and fecal loss of alpha-1 antitrypsin depicts the plasma concentration of alpha-1 antitrypsin as;


Alpha 1-AT plasma concentration = ((stool volume) x (stool alpha 1-AT)) / (serum alpha-1 AT)
Alpha 1-AT plasma concentration = ((stool volume) x (stool alpha 1-AT)) / (serum alpha-1 AT)


[[Gastrointestinal]] loss of alpha-1 antitrypsin is measured in feces and a clearance greater than 27mL/day is considered diagnostic for protein losing enteropathy.<ref name="pmid6973500">{{cite journal| author=Florent C, L'Hirondel C, Desmazures C, Aymes C, Bernier JJ| title=Intestinal clearance of alpha 1-antitrypsin. A sensitive method for the detection of protein-losing enteropathy. | journal=Gastroenterology | year= 1981 | volume= 81 | issue= 4 | pages= 777-80 | pmid=6973500 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=6973500  }}</ref>
[[Gastrointestinal]] loss of alpha-1 antitrypsin is measured in feces and a clearance greater than 27mL/day is considered diagnostic for protein losing enteropathy.


*51Cr-labeled albumin can also be measured followed by stool collection to determine the amount of protein loss into the gastrointestinal tract.
*51Cr-labeled albumin can also be measured followed by stool collection to determine the amount of protein loss into the gastrointestinal tract.


==='''Imaging Studies'''===
==='''Imaging Studies'''===
Following the detection of abnormal amounts of alpha-1 antitrypsin in the stool, the following tests can be performed to detect the specific etiology for the protein loss into the gastrointestinal lumen.<ref name="LevittLevitt20172">{{cite journal|last1=Levitt|first1=David|last2=Levitt|first2=Michael|title=Protein losing enteropathy: comprehensive review of the mechanistic association with clinical and subclinical disease states|journal=Clinical and Experimental Gastroenterology|volume=Volume 10|year=2017|pages=147–168|issn=1178-7023|doi=10.2147/CEG.S136803}}</ref>
Following the detection of abnormal amounts of alpha-1 antitrypsin in the stool, the following tests can be performed to detect the specific etiology for the protein loss into the gastrointestinal lumen.


*Administration of [[technetium-99]] labeled macromolecules such as [[albumin]]. Imaging is required to localize the primary site of protein leakage with no requirement for fecal collection. [[Scintigraphy]] is becoming popular in the diagnosis and localization of the site of protein leakage.  
*Administration of [[technetium-99]] labeled macromolecules such as [[albumin]]. Imaging is required to localize the primary site of protein leakage with no requirement for fecal collection. [[Scintigraphy]] is becoming popular in the diagnosis and localization of the site of protein leakage.  

Revision as of 14:41, 10 February 2021

WikiDoc Resources for Protein losing enteropathy

Articles

Most recent articles on Protein losing enteropathy

Most cited articles on Protein losing enteropathy

Review articles on Protein losing enteropathy

Articles on Protein losing enteropathy in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Protein losing enteropathy

Images of Protein losing enteropathy

Photos of Protein losing enteropathy

Podcasts & MP3s on Protein losing enteropathy

Videos on Protein losing enteropathy

Evidence Based Medicine

Cochrane Collaboration on Protein losing enteropathy

Bandolier on Protein losing enteropathy

TRIP on Protein losing enteropathy

Clinical Trials

Ongoing Trials on Protein losing enteropathy at Clinical Trials.gov

Trial results on Protein losing enteropathy

Clinical Trials on Protein losing enteropathy at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Protein losing enteropathy

NICE Guidance on Protein losing enteropathy

NHS PRODIGY Guidance

FDA on Protein losing enteropathy

CDC on Protein losing enteropathy

Books

Books on Protein losing enteropathy

News

Protein losing enteropathy in the news

Be alerted to news on Protein losing enteropathy

News trends on Protein losing enteropathy

Commentary

Blogs on Protein losing enteropathy

Definitions

Definitions of Protein losing enteropathy

Patient Resources / Community

Patient resources on Protein losing enteropathy

Discussion groups on Protein losing enteropathy

Patient Handouts on Protein losing enteropathy

Directions to Hospitals Treating Protein losing enteropathy

Risk calculators and risk factors for Protein losing enteropathy

Healthcare Provider Resources

Symptoms of Protein losing enteropathy

Causes & Risk Factors for Protein losing enteropathy

Diagnostic studies for Protein losing enteropathy

Treatment of Protein losing enteropathy

Continuing Medical Education (CME)

CME Programs on Protein losing enteropathy

International

Protein losing enteropathy en Espanol

Protein losing enteropathy en Francais

Business

Protein losing enteropathy in the Marketplace

Patents on Protein losing enteropathy

Experimental / Informatics

List of terms related to Protein losing enteropathy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Synonyms and keywords: Protein loss, protein deficiency, GI protein loss, gastrointestinal protein loss, protein-losing gastroenteropathy, protein-losing gastroenteropathy, gastroenteropathy, gastric protein loss, helicobacter pylori, H pylori, giant hypertrophic gastropathy, menetrier disease, ménétrier, disease, loss of plasma proteins from the gastrointestinal tract, excessive leakage of plasma proteins into the lumen of the gastrointestinal tract, lymphatic obstruction, mucosal disease with erosions, ulcerations, swelling of the legs, peripheral edema, decreased plasma oncotic pressure

Overview

Protein losing enteropathy is the loss of plasma proteins from the gastrointestinal tract caused by an array of abnormalities

Common Causes

Most cases of protein losing enteropathy are caused as a result of:

  1. Primary gastrointestinal disorders
  2. Lymphatic obstruction

Primary Gastrointestinal Diseases

Mucosal Erosions/Ulcerations

Primary gastrointestinal diseases causing erosion or ulceration of the mucosa of the gut leading to fecal loss of proteins such as:

Non-Erosive/Ulcerative Mucosal involvement

Lymphatic Obstruction

Conditions responsible for causing lymphatic obstruction leading to the leakage of lymph into the lumen of gut such as:

Complete Differential Diagnosis Of Underlying Causes

Diagnosis

As hypoproteinemia is the key factor in evaluating a patient for protein losing enteropathy, other common causes of hypoproteinemia such as nephrotic syndrome, impaired protein synthesis due to chronic liver disease and malnutrition must be excluded first.

Laboratory Studies

As the most prominent laboratory finding is a decrease in serum concentration of albumin and globulin, the diagnostic work up protein losing enteropathy consist of quantitative measurements of Alpha-1 antitrypsin or 51Cr-albumin.

  • Alpha-1 antitrypsin (A1AT) used as an endogenous marker is a sensitive and inexpensive laboratory test performed to diagnose protein losing enteropathy and has become the current standard for quantitating protein losing enteropathy. Measurement of fecal volume and fecal loss of alpha-1 antitrypsin depicts the plasma concentration of alpha-1 antitrypsin as;

Alpha 1-AT plasma concentration = ((stool volume) x (stool alpha 1-AT)) / (serum alpha-1 AT)

Gastrointestinal loss of alpha-1 antitrypsin is measured in feces and a clearance greater than 27mL/day is considered diagnostic for protein losing enteropathy.

  • 51Cr-labeled albumin can also be measured followed by stool collection to determine the amount of protein loss into the gastrointestinal tract.

Imaging Studies

Following the detection of abnormal amounts of alpha-1 antitrypsin in the stool, the following tests can be performed to detect the specific etiology for the protein loss into the gastrointestinal lumen.

  • Administration of technetium-99 labeled macromolecules such as albumin. Imaging is required to localize the primary site of protein leakage with no requirement for fecal collection. Scintigraphy is becoming popular in the diagnosis and localization of the site of protein leakage.  
  • For the diagnosis of lymphatic obstruction, computed tomography, lymphangiography or magnetic resonance imaging can be used.

Other tests:

  • Biopsy samples of the mucosa and stool cultures for ova and parasites should be performed if there is a suspicion of ulcerative or erosive gastrointestinal disease and parasitic infection, respectively.

Treatment

Treatment depends upon the underlying condition.

Template:SIB
hu:Enterális fehérjevesztő-szindróma

Template:WH Template:WS